AHB-137 effective for chronic hepatitis B: Phase 2b clinical trial
AHB-137, Ausperbio’s experimental therapy, safely and effectively suppressed the disease-causing hepatitis B virus (HBV) in people with chronic hepatitis B, according to interim…
AHB-137, Ausperbio’s experimental therapy, safely and effectively suppressed the disease-causing hepatitis B virus (HBV) in people with chronic hepatitis B, according to interim…
The efficacy of Livdelzi (seladelpar) at treating primary biliary cholangitis (PBC) is similar irrespective of whether patients previously received other medications, according to…
An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…
Children with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, are more than 40 times more likely to die than…
Researchers have identified a new mutation in the JAG1 gene as the likely cause of Alagille syndrome in an 18-year-old man who also had persistent…
Hepatitis Awareness Month is held every May to raise awareness about viral hepatitis, an inflammation of the liver caused by a virus, and help…
With ESP-1336 as their lead candidate, Esperion Therapeutics is developing new treatments for primary sclerosing cholangitis (PSC) by targeting an enzyme called ACLY.
Exposure to high levels of fine particulate matter, or PM2.5, the most commonly studied air pollutant, and reduced time in the sunlight in the three…
The U.S. Food and Drug Administration and Health Canada are reviewing Novo Nordisk‘s requests to approve semaglutide’s under-the-skin formulation, at a dose of 2.4…
Transient elastography, a noninvasive test that uses ultrasound to detect liver stiffness, may help to differentiate biliary atresia from other underlying diseases in infants…